← 홈

ADC · 다발성 골수종

40개 · ADC 1048 · Antibody 5323 · CGT 2737 · 다음 갱신 D-14 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 40개
ADCAHOTFDACuratedFDABiologicGSKMMAFApproved

belantamab mafodotin (Blenrep, GSK2857916)

Multiple myeloma · BCMA

#BCMA#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 57%임상시험 76상태 DISCONTINUED
ADCCBiologicChristopher StrousePhase 2

Sirolimus (Sirolimus)

Multiple Myeloma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+3
효능 ORR 9%임상시험 81상태 DISCONTINUED
ADCBBiologicMerck Sharp & Dohme LLCPhase 2

Cytoxan (Cytoxan)

Multiple Myeloma, Refractory · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 95%임상시험 73상태 RECRUITING
ADCBBiologicPalleos Healthcare GmbHvedotin, vinblastine, and d…Phase 2

Adriamycin (Adriamycin)

Multiple Myeloma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 95%임상시험 70상태 ACTIVE
ADCABiologicstaleGSKcys-mcMMAFPhase 3

belantamab mafodotin (Blenrep, GSK2857916)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 100%임상시험 69상태 RECRUITING
ADCBiologicK36 Therapeutics, Inc.Phase 2

Dexamethasone oral (Dexamethasone oral)

Multiple Myeloma · Breast Neoplasms

#BreastNeoplasms#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 90%임상시험 62상태 RECRUITING
ADCBiologicCelyad Oncology SAPhase 2

Endoxan (Endoxan)

Relapse/Refractory Multiple Myeloma · Lymphoma, T-Cell, Peripheral

#LymphomaT-CellPeripheral#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 95%임상시험 62상태 ACTIVE
ADCBiologicKaryopharm Therapeutics IncPhase 2

Clarithromycin (Clarithromycin)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#인기#항체약물접합체+2
효능 ORR 6%임상시험 59상태 RECRUITING
ADCBiologicAmerican Society of Clinical On…Phase 2

Dabrafenib plus Trametinib (Dabrafenib plus Trametinib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 100%임상시험 57상태 RECRUITING
ADCBiologicFortis Therapeutics, Inc.Phase 2

FOR46 (FOR46)

Multiple Myeloma; Multiple Myeloma in Relapse · Prostate Cancer Metastatic

#ProstateCancerMetastatic#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 51.5%임상시험 55상태 RECRUITING
ADCBiologicPfizerPhase 3

Iberdomide (Iberdomide)

Multiple Myeloma · FRα

#FR#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 92.9%임상시험 47상태 RECRUITING
ADCBiologicSanofiPhase 2

Belumosudil (Belumosudil)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 74%임상시험 38상태 RECRUITING
ADCBiologicJanssen Research & Development,…Phase 2

Nirogacestat (Nirogacestat)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 57%임상시험 32상태 RECRUITING
ADCBiologicstaleAmerican Society of Clinical On…Phase 2

Vemurafenib and Cobimetinib (Vemurafenib and Cobimetinib)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 65%임상시험 30상태 RECRUITING
ADCBiologicstaleGlaxoSmithKlinePhase 1

GSK2857916 (GSK2857916)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 100%임상시험 29상태 ACTIVE
ADCBiologicstaleDaiichi SankyoPhase 2

TDxD (Fam-Trastuzumab Deruxtecan-Nxki, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 71.7%임상시험 27상태 RECRUITING
ADCBiologicstaleYOUNGIL KOHPhase 2

Mezigdomide (Mezigdomide)

Relapsed Refractory Multiple Myeloma (RRMM) · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 23상태 RECRUITING
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab Mafodotin-Blmf)

Multiple Myeloma; Multiple Myeloma in Relapse · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 6%임상시험 9상태 RECRUITING
ADCBiologicstaleCanadian Myeloma Research GroupPhase 2

GSK2857916 with Pomalidomide and Dexamethasone (GSK2857916 with Pomalidomide and Dexamethasone)

Relapsed and/or Refractory Multiple Myeloma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 100%임상시험 7상태 RECRUITING
ADCBiologicstaleGSKPhase 2

belantamab mafodotin (Blenrep, GSK2857916, Belantamab mafodotin lyophilized powder)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 34%임상시험 6상태 ACTIVE

1 / 2 페이지

← 이전다음 →